On August 31, 2023, Mark Eisner, M.D. resigned from his position as Chief Medical Officer of FibroGen, Inc., effective September 8, 2023, to pursue other opportunities. Dr. Eisner will continue as an employee through the effective date of his resignation, after which time, he will serve the company as a consultant under a consulting agreement (the ?Consulting Agreement?) to provide transition services. The company has commenced a search for a new Chief Medical Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.04 USD | +1.96% | -9.57% | +17.34% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.34% | 103M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FGEN Stock
- News FibroGen, Inc.
- Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023